Skip to main content
"The cellular receptor for SARS-CoV-2 is ACE2 (5). Recombinant human ACE2 (rhACE2, or APN01) is currently under development as a treatment for acute lung injury and pulmonary arterial hypertension and has proven well tolerated in a phase 1 trial in healthy volunteers. rhACE2 has been shown to significantly reduce viral entry into human cell–derived organoids (6), presumably by acting as a decoy for virus binding. This has lent support to the clinical trials that are investigating blockade of viral entry with APN01 for COVID-19 patients."

Read more here.